Jane Knöchel

An oral antisense oligonucleotide for PCSK9 inhibition

Peter Gennemark, Katrin Walter, Niclas Clemmensen et al. · Science Translational Medicine · 2021 · 117 citations

AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials

Javier Armisen, Mitra Rauschecker, Janeli Sarv et al. · Journal of Hepatology · 2025 · 32 citations

Medicine, Immunology, Clinical Trials +8

Hepatic patatin‐like phospholipase domain‐containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans

Elke Ericson, Linnéa Bergenholm, Anne‐Christine Andréasson et al. · Hepatology Communications · 2022 · 21 citations · Full text

ETESIAN: A PHASE 2B STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF AZD8233, A PCSK9-TARGETED ANTISENSE OLIGONUCLEOTIDE, IN PATIENTS WITH DYSLIPIDEMIA

Michael J. Koren, Alexis Hofherr, Jennifer Schumi et al. · Journal of the American College of Cardiology · 2022 · 16 citations

The Efficacy, Lipid Disorder, Medicine +7

AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval

Dinko Rekić, I. A. Azarov, Jane Knöchel et al. · British Journal of Clinical Pharmacology · 2022 · 15 citations · Full text